Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease

Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease

(2018) S. Singh et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Medical Therapies for Fistulizing Crohn’s Disease: Systematic Review and Meta-Analysis

(2018) Matthew J. Lee et al.   Clinical Gastroenterology and Hepatology

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease

(2018) Paul Rutgeerts et al.   GASTROENTEROLOGY

Natalizumab in the treatment of Crohn’s disease patients

(2017) Cristiano Pagnini et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

(2017) Bruce E. Sands et al.   GASTROENTEROLOGY

OP010 Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years

(2017) W. Sandborn et al.   Journal of Crohns & Colitis

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

(2017) Paula Dávila-Seijo et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry

(2017) David Fiorentino et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Genetics and Pathogenesis of Inflammatory Bowel Disease

(2016) Ta-Chiang Liu et al.   Annual Review of Pathology-Mechanisms of Disease

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease

(2016) Alessandro Armuzzi et al.   DIGESTIVE AND LIVER DISEASE

Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature

(2016) X. Cortes et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Long-term Efficacy of Vedolizumab for Crohn’s Disease

(2016) Severine Vermeire et al.   Journal of Crohns & Colitis

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

(2015) N. S. Ding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

(2015) Glen S. Hazlewood et al.   GASTROENTEROLOGY

Briakinumab for Treatment of Crohnʼs Disease

(2015) Remo Panaccione et al.   INFLAMMATORY BOWEL DISEASES

Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis

(2015) E. Galli-Novak et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Natural history and long-term clinical course of Crohn’s disease

(2014) Hugh James Freeman   WORLD JOURNAL OF GASTROENTEROLOGY

American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease

(2013) Jonathan P. Terdiman et al.   GASTROENTEROLOGY

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

(2013) Cornelia Tillack et al.   GUT

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues

(2013) Jochem H Bernink et al.   NATURE IMMUNOLOGY

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Discovery and mechanism of ustekinumab

(2012) Jacqueline M. Benson et al.   mAbs

IL-12 family cytokines: immunological playmakers

(2012) Dario A A Vignali et al.   NATURE IMMUNOLOGY

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy

(2011) S. Danese et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Epidemiology and Natural History of Inflammatory Bowel Diseases

(2011) Jacques Cosnes et al.   GASTROENTEROLOGY

IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease

(2011) Alessandra Geremia et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Functional Studies on the IBD Susceptibility Gene IL23R Implicate Reduced Receptor Function in the Protective Genetic Variant R381Q

(2011) Svetlana Pidasheva et al.   PLoS One

Inflammatory Bowel Disease

(2010) Arthur Kaser et al.   Annual Review of Immunology

Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

(2010) Pauline L. Martin et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Cytokine Requirements for the Differentiation and Expansion of IL-17A- and IL-22-Producing Human V 2V 2 T Cells

(2010) K. J. Ness-Schwickerath et al.   JOURNAL OF IMMUNOLOGY

Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology

(2010) Sofia Buonocore et al.   NATURE

Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells

(2010) J. J. O'Shea et al.   SCIENCE

The Genetics of Crohn's Disease

(2009) Johan Van Limbergen et al.   Annual Review of Genomics and Human Genetics

Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans

(2009) Lyudmila Lyakh et al.   IMMUNOLOGICAL REVIEWS

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Alternative Activation of Macrophages: An Immunologic Functional Perspective

(2008) Fernando O. Martinez et al.   Annual Review of Immunology

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

IL-23 modulates CD56+/CD3- NK Cell and CD56+/CD3+ NK-like T Cell function differentially from IL-12

(2008) D. van de Wetering et al.   INTERNATIONAL IMMUNOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY